Comparative Pharmacology
Head-to-head clinical analysis: N E E 1 35 28 versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: N E E 1 35 28 versus SIMPESSE.
N.E.E. 1/35 28 vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin (FSH and LH) release, preventing ovulation. Also cause cervical mucus thickening and endometrial changes.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet orally once daily for 28 days; each tablet contains norethindrone 1 mg and ethinyl estradiol 35 mcg.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Ethinyl estradiol: ~15-19 hours (linear pharmacokinetics); Norethindrone: ~7-9 hours (terminal half-life; steady-state achieved within 5-7 days)
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Renal: ~50-60% (metabolites, primarily glucuronide conjugates); Fecal: ~30-40% (biliary excretion of metabolites); Unchanged drug: <5%
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive